

*National Imaging Associates, Inc.	
Clinical guidelines	Original Date: September 1997
MUGA (Multiple Gated Acquisition) Scan	
CPT Codes: 78472, 78473, 78494, +78496	Last Revised Date: April 2023
Guideline Number: NIA_CG_027	Implementation Date: January 2024

GENERAL INFORMATION

- It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.
- Where a specific clinical indication is not directly addressed in this guideline, medical necessity determination will be made based on widely accepted standard of care criteria. These criteria are supported by evidence-based or peer-reviewed sources such as medical literature, societal guidelines and state/national recommendations.

Indications for Multiple Gated Acquisition (MUGA) Scan¹


- To evaluate left ventricular function in a patient with coronary artery disease, valvular heart disease, myocardial disease, or congenital heart disease, in any of the following scenarios:
 - When ventricular function is required for management, and transthoracic echocardiography (TTE) or other imaging has proven inadequate^{2, 3}
 - When there are conflicting results between other testing (i.e., Myocardial Perfusion Imaging and TTE) in the measurement of ejection fraction (EF), and the results of the MUGA will help in the management of the patient
 - Prior TTE has demonstrated systolic dysfunction (EF < 50%) and management will change based on the results of the MUGA scan
- In the course of treatment with cardiotoxic medication when TTE images are inadequate to evaluate left ventricular systolic function²⁻⁶:
 - Baseline assessment prior to initiation of therapy
 - Monitoring during therapy. The frequency of testing should be left to the discretion of the ordering provider but in the absence of new abnormal findings, generally no more often than every 6 weeks while on active therapy

 Long term surveillance after completion of therapy may be required, especially for those who have been exposed to anthracycline medication. The frequency of testing is generally every 6-12 months, or at the discretion of the provider

BACKGROUND^{2, 7-9}

Multiple-gated acquisition (MUGA) scanning uses radiolabeled red blood cells to scan right and left ventricular images in a cine loop format that is synchronized with the electrocardiogram.


A prior MUGA scan is not an indication for repeat MUGA (if another modality would be suitable, i.e., TTE).





Abbreviations

EF	Ejection Fraction
MUGA	Multiple Gated Acquisition (nuclear scan of ventricular function)
TTE	Transthoracic echocardiography





REFERENCES

1. Doherty JU, Kort S, Mehran R, et al. ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2019 Appropriate Use Criteria for Multimodality Imaging in the Assessment of Cardiac Structure and Function in Nonvalvular Heart Disease: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and the Society of Thoracic Surgeons. *J Am Coll Cardiol*. Feb 5 2019;73(4):488-516. doi:10.1016/j.jacc.2018.10.038

2. Patel MR, White RD, Abbara S, et al. 2013 ACCF/ACR/ASE/ASNC/SCCT/SCMR appropriate utilization of cardiovascular imaging in heart failure: a joint report of the American College of Radiology Appropriateness Criteria Committee and the American College of Cardiology Foundation Appropriate Use Criteria Task Force. *J Am Coll Cardiol*. May 28 2013;61(21):2207-31. doi:10.1016/j.jacc.2013.02.005

3. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. May 3 2022;145(18):e876-e894. doi:10.1161/cir.000000000001062

4. Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. Sep 2014;27(9):911-39. doi:10.1016/j.echo.2014.07.012

5. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). *Eur Heart J*. Sep 21 2016;37(36):2768-2801. doi:10.1093/eurheartj/ehw211

6. Baldassarre LA, Ganatra S, Lopez-Mattei J, et al. Advances in Multimodality Imaging in Cardio-Oncology: JACC State-of-the-Art Review. *J Am Coll Cardiol*. Oct 18 2022;80(16):1560-1578. doi:10.1016/j.jacc.2022.08.743

7. Friedman JD, Berman DS, Borges-Neto S, et al. First-pass radionuclide angiography. *J Nucl Cardiol*. Nov 2006;13(6):e42-55. doi:10.1016/j.nuclcard.2006.08.006


8. Mitra D, Basu S. Equilibrium radionuclide angiocardiography: Its usefulness in current practice and potential future applications. *World J Radiol*. Oct 28 2012;4(10):421-30. doi:10.4329/wjr.v4.i10.421

9. Ritchie JL, Bateman TM, Bonow RO, et al. Guidelines for clinical use of cardiac radionuclide imaging. Report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Radionuclide Imaging), developed in collaboration with the American Society of Nuclear Cardiology. *J Am Coll Cardiol*. Feb 1995;25(2):521-47. doi:10.1016/0735-1097(95)90027-6



POLICY HISTORY

Date	Summary
April 2023	 Added statement on clinical indications not addressed in this guideline
February 2022	No significant changes





Reviewed / Approved by NIA Clinical Guideline Committee

Disclaimer: National Imaging Associates, Inc. (NIA) authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Evolent Health LLC subsidiaries including, but not limited to, National Imaging Associates ("NIA"). The policies constitute only the reimbursement and coverage guidelines of NIA. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. NIA reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.

